Retrospective multicentre matched cohort study comparing safety and efficacy outcomes of intermittent-infusion versus continuous-infusion vancomycin. (9th January 2020)

• Record Type: Journal Article
• Authors: Ma, Nathan H; Walker, Sandra A N; Elligsen, Marion; Kiss, Alex; Palmay, Lesley; Ho, Grace; Powis, Jeff; Bansal, Vikas; Leis, Jerome A
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 75:Number 4(2020)
• Page Start: 1038
• Page End: 1046
• Publication Date: 2020-01-09
• Subjects: Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dkz531
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract: Background: Patients with good renal function receiving intermittent-infusion vancomycin (IIV) may require total daily doses ≥4 g to achieve trough concentrations of 15–20 mg/L, increasing the risk of vancomycin-associated nephrotoxicity. Continuous-infusion vancomycin (CIV) may be associated with a lower risk of vancomycin-associated nephrotoxicity compared with IIV, but studies comparing safety of both dosing strategies are lacking. Objectives: To compare the risk of nephrotoxicity with CIV versus IIV when target concentration ranges were the same with both dosing modalities. Methods: A retrospective multicentre matched cohort study of admitted patients between 1 January 2010 and 31 December 2016 was completed. Adult patients who received ≥48 h of vancomycin with at least one steady-state vancomycin concentration were eligible. The primary outcome was to compare the rates of nephrotoxic risk and renal injury, defined by the RIFLE criteria, between CIV and IIV. Results: Of 2136 patients who received vancomycin during the study period, 146 CIV patients were eligible and matched to 146 IIV patients. After adjustment of potential confounders, CIV was found to have a lower odds of developing nephrotoxic risk (OR 0.42, 95% CI 0.21–0.98, P = 0.025) and renal injury (OR 0.19, 95% CI 0.05–0.59, P = 0.004). Conclusions: CIV is associated with a lower odds of nephrotoxicity compared with IIV when targeting the same concentration range and should be an alternative dosing strategy for patients who will receive prolonged therapy or require >4 g/day to achieve therapeutic levels.